Arruda Liã Bárbara, Fonseca Luiz Augusto M, Duarte Alberto J S, Casseb Jorge
Institute of Tropical Medicine of São Paulo at the São Paulo University, Brazil.
AIDS Res Hum Retroviruses. 2010 Jan;26(1):105-7. doi: 10.1089/aid.2009.0179.
The presence of mutations associated with integrase inhibitor (INI) resistance among INI-naive patients may play an important clinical role in the use of those drugs Samples from 76 HIV-1-infected subjects naive to INIs were submitted to direct sequencing. No differences were found between naive (25%) subjects and subjects on HAART (75%). No primary mutation associated with raltegravir or elvitegravir resistance was found. However, 78% of sequences showed at least one accessory mutation associated with resistance. The analysis of the 76 IN sequences showed a high polymorphic level on this region among Brazilian HIV-1-infected subjects, including a high prevalence of aa substitutions related to INI resistance. The impact of these findings remains unclear and further studies are necessary to address these questions.
初治患者中存在与整合酶抑制剂(INI)耐药相关的突变可能在这些药物的使用中发挥重要临床作用。将76例初治的HIV-1感染受试者的样本进行直接测序。初治受试者(25%)与接受高效抗逆转录病毒治疗(HAART)的受试者(75%)之间未发现差异。未发现与拉替拉韦或埃替拉韦耐药相关的原发性突变。然而,78%的序列显示至少有一个与耐药相关的辅助性突变。对76个整合酶(IN)序列的分析表明,在巴西HIV-1感染受试者中,该区域具有高度多态性,包括与INI耐药相关的氨基酸替代的高流行率。这些发现的影响尚不清楚,需要进一步研究来解决这些问题。